Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm | Latest News RSS feed

Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm - Latest News

SGLT2 inhibitors: an emerging option for cardiologists?

But Boehringer’s trial goes beyond improved CV outcomes for diabetes patients to consider its product’s role for ... the use of SGLT2 inhibitors for the treatment of heart failure patients without typ... read more

Some Second-Line T2D Options Linked With CV Risk

"This calls for a paradigm shift in the treatment ... DPP-4 inhibitors, or SGLT-2 inhibitors more routinely after metformin rather than sulfonylureas or basal insulin," O'Brien and colleagues continue... read more

How The Global Pharma Industry Will Shape Up In The Next 5 Years?

The 39 novel drugs approved in FY 2012 includes groundbreaking treatment for a form of cystic fibrosis, the first human cord blood product ever approved, and the first drugs to treat advanced basal .. ... read more

Looking for another news?

FDA clears Jardiance combo for type 2 diabetes

While their metformin combination lagged behind rivals, Boehringer and Lilly were the first to get approval in the US for a combination of an SGLT2 inhibitor with a DPP-4 inhibitor, a class which prom... read more

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control

This article provides an overview of the paradigm shift that triggered ... The concept of inhibition of SGLT-2 marks a departure in how diabetes is viewed and approached for treatment. SGLT-2 inhibito... read more

Hope seen for type 1 diabetes fix, but obesity clouds type 2 outlook

But interim steps like these while the science of diabetes care continues to advance "are helpful to patients," Moller told BioWorld Insight ... LLC for rights to develop and commercialize an SGLT2 in... read more

Two Diabetes Drug Mysteries

The SGLT-2 inhibitors are a class of diabetes medications that work ... But there was also an unexpected increased in the risk of amputation (which is already a risk in advanced Type II diabetes patie... read more

Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy

Careful patient screening and monitoring during treatment ... Rapamycin Inhibitors–Induced Insulin Resistance and Hyperglycemia The phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin ( ... read more

Bolstering your armamentarium with SGLT2 inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are newer agents available for the treatment of type 2 diabetes mellitus ... option in treating patients with T2DM and have provided a paradigm shift ... read more

Poxel Provides Business Update and Reports Results for Full Year 2017

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... Phase 1 and 2 programs. ... read more

2017 Brands of the Year: 5 Impact Areas

The industry press has suggested that Jardiance’s rise could be slowed in the event of positive CV outcomes data for other SGLT2 inhibitor drugs ... Jardiance for the treatment of people, both with an... read more

The year of the blockbuster

Following an advanced analysis of the database ... Steglatro (ertugliflozin) from Pfizer and Merck: Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest oral treatment options for diabet... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us